Curanex Pharmaceuticals Inc (NASDAQ:CURX) Sees Large Decrease in Short Interest

Curanex Pharmaceuticals Inc (NASDAQ:CURX) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 449 shares, a decrease of 98.2% from the August 15th total of 24,375 shares. Based on an average trading volume of 35,024 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are short sold.

Curanex Pharmaceuticals Trading Up 2.6%

Shares of CURX traded up $0.11 during midday trading on Thursday, reaching $4.31. 24,177 shares of the stock were exchanged, compared to its average volume of 33,791. Curanex Pharmaceuticals has a 52 week low of $3.58 and a 52 week high of $183.59. The company’s 50 day moving average is $4.36 and its two-hundred day moving average is $6.47. The company has a market capitalization of $6.77 million and a P/E ratio of -0.55.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Curanex Pharmaceuticals

An institutional investor recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC acquired a new position in Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.